|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While the DBH polymorphism (rs1611115) was also associated with increased AD risk (OR = 1.1, p = 0.04) the synergistic interaction (SF = 2.2, p = 0.007) between BDNF (rs6265) and DBH (rs1611115) contributed greater AD risk than either gene alone, an effect that was greater in women (SF = 2.4, p = 0.04) than men (SF = 2.0, p = 0.2).
|
30909233 |
2019 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prefrontal cortex BDNF gene expression is associated with aging, rs6265 carrier status, and AD neuropathology in a variant-specific manner that seems to be independent of DNA methylation influences.
|
31127785 |
2019 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57).
|
28984138 |
2018 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.Ann Neurol 2018;84:424-435.
|
30014553 |
2018 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29896439 |
2018 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To compare the results of neuropsychological tests, evoked potentials N200 and P300 and polymorphisms of ApoE and BDNF rs6265 between patients with normal cognition and those with mild cognitive impairment (MCI) and Alzheimer's dementia (AD).
|
28833437 |
2018 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57).
|
28984138 |
2018 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29896439 |
2018 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.Ann Neurol 2018;84:424-435.
|
30014553 |
2018 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
|
28720165 |
2017 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, we observed a clear female-specific risk trend for the effect of rs6265</span> on AD endophenotypes.
|
28202203 |
2017 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results suggest that the <i>BDNF</i> Val66Met polymorphism may play an important role in cognitive decline and could be considered as a target for novel AD therapeutics.
|
28468845 |
2017 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic analysis revealed rs2030324 and rs6265 were associated with aMCI and rs6265 was associated with AD conversion.
|
28387675 |
2017 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression.
|
27335045 |
2017 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results suggest that the <i>BDNF</i> Val66Met polymorphism may play an important role in cognitive decline and could be considered as a target for novel AD therapeutics.
|
28468845 |
2017 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
|
28720165 |
2017 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression.
|
27335045 |
2017 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
SEE ROGAEVA AND SCHMITT-ULMS DOI101093/AWW201 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease.
|
27521573 |
2016 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dose-dependent genotype effects of BDNF Val66Met polymorphism on default mode network in early stage Alzheimer's disease.
|
27494844 |
2016 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dose-dependent genotype effects of BDNF Val66Met polymorphism on default mode network in early stage Alzheimer's disease.
|
27494844 |
2016 |
|
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
SEE ROGAEVA AND SCHMITT-ULMS DOI101093/AWW201 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease.
|
27521573 |
2016 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to investigate the GAB2 rs2373115 and BDNF rs6265 polymorphisms and the risk of AD in a Brazilian sample.
|
25853819 |
2015 |
|
rs6265
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis confirmed the gender-related association between BDNF 196A/G polymorphism and AD risk, which may indicate a certain effect of female hormone on progression of the disease.
|
24279351 |
2014 |